中文 | English

产品展示 products
Featured Products
Parmaceutical Ingredients
Anticancer
Antifungal
Cardiovascular
Anti-diabetics/hypertensive
Psychiatric
Industrial Chemicals
Sodium Lignosulphonate
Calcium Lignosulphonate
Sodium Naphthalene Sulfonate
PCE Superplasticizer
Sodium Gluconate
PCE Monomers
Intermediates
Other Compounds
position:home
Strontium Ranelate Restrictions Recommended in EU

The product information for strontium ranelate (Protos) has been updated following European Medicines Agency reports that it may increase the risk of serious heart problems, including myocardial infarction.

These findings came from an analysis by the EMA of pooled data from randomised, placebo-controlled clinical studies, performed as part of a routine safety assessment.

The TGA-approved indication is now for treatment of severe (established) osteoporosis in men at increased risk of fracture and for treatment of severe (established) osteoporosis in postmenopausal women who are at high risk of fracture.

New contraindications have also been added to include people with a history of, or currently experiencing, a range of heart or circulatory problems.


copyright   Jinan Sente Chemical Co.,Ltd.
Address: No.25 Chaoshan Street, Lixia District, Jinan , China - 250100
技术支持:济南久联